TruBlk Shilajit Resin Outperformed Placebo on Erectile Function and Testosterone
A 90-day randomized trial found that TruBlk™ Shilajit resin improved sexual function more than placebo in men with mild-to-moderate erectile dysfunction and symptoms suggestive of androgen deficiency. The signal was not confined to one questionnaire score or one laboratory marker. Erectile function, several dimensions of sexual performance, total and free testosterone, fatigue, and selected hypogonadism-related symptoms all moved in the same direction.
The study enrolled 100 men aged 35–55 years across two sites and used a double-blind, placebo-controlled design. Participants received 250 mg twice daily of standardized Shilajit resin or matched placebo. Erectile dysfunction was defined by an IIEF erectile function domain score between 11 and 25, which places the cohort in the mild-to-moderate range rather than the severe end of the spectrum. That matters because men in this band often retain enough baseline function to detect improvement within a 3-month window, especially if the intervention affects libido, energy, or hormonal signaling in parallel with vascular response.
The endpoint set was broad. Investigators tracked change from baseline in IIEF total and domain scores, total and free testosterone, cortisol, and HIS-Q domains. Secondary measures included nitric oxide, fatigue, global assessments, and semen parameters in a subset. Such breadth is useful in a condition like erectile dysfunction, where the complaint is often the visible tip of a wider endocrine and psychosocial syndrome. A drug that improves only one layer of that syndrome can still leave the patient dissatisfied; a product that touches several layers is more likely to produce a meaningful bedside response.
Sexual Function Gains Extended Across Multiple Domains
By day 90, the IIEF total score improved more in the Shilajit arm than in the placebo arm, with a relative increase of +32.1% versus +13.6% and a between-group effect size of d=0.67 (p=0.005). Four of the five IIEF domains showed significant benefit: erectile function, orgasmic function, overall satisfaction, and intercourse satisfaction. Sexual desire improved as well, but the effect was smaller and did not reach statistical significance.
One sentence captures the clinical pattern: this was not a cosmetic shift in questionnaire scores.
The domain distribution is clinically informative. Erectile function reflects the mechanical and vascular dimensions of the problem, but orgasmic function and satisfaction scores often reflect whether the patient experiences the change as real and repeatable. In men with borderline androgen deficiency, those domains can improve together if the intervention alters central sexual motivation, peripheral hemodynamics, and confidence in performance. The smaller effect on sexual desire suggests that not every psychosexual component shifted at the same pace, or that desire may require a longer exposure window to separate from placebo effects.
Testosterone Rose While Cortisol Was Not the Central Story
Shilajit also produced meaningful hormonal changes. Total testosterone rose by 46.1% in the active group versus 10.0% with placebo, and free testosterone increased by 37.4% versus 6.8%. Both comparisons reached statistical significance. Those changes are large enough to be clinically relevant in a cohort already selected for symptoms suggestive of androgen deficiency.
The biological plausibility is straightforward. Testosterone influences libido, nocturnal erections, mood, energy, and aspects of endothelial and smooth-muscle function that can shape erection quality. A therapy that raises both total and free testosterone may therefore improve sexual performance through more than one route at once. That may also explain why the IIEF response and the fatigue response moved together rather than drifting apart.
Cortisol was part of the registered primary endpoint set, but the abstract does not provide a comparative change signal for that marker. Nitric oxide likewise did not show a significant between-group difference. The absence of a nitric oxide signal does not weaken the overall trial signal, but it does argue against a simplistic mechanistic story in which the product works solely by altering one vasodilator pathway. Erectile physiology is layered, and androgen status, sleep, energy, and vascular responsiveness can all contribute to the final clinical picture.
Fatigue and Hypogonadism-Related Symptoms Improved Sharply
The fatigue result stands out. Fatigue Severity Scale scores dropped by 51.8% with TruBlk™ versus 27.4% with placebo, producing a large between-group effect at day 90 (d=−1.13, p